Humira Horsepower: AbbVie’s Brand Retains 98% US Market Share

Amgen’s Amjevita, the first biosimilar of Humira to launch in the US, hasn’t made headway into the US market, according to Samsung Bioepis’ quarterly market report on the US biosimilars market.

resilient
AbbVie's Humira has demonstrated resilience in the market • Source: Shutterstock

AbbVie Inc.’s branded Humira (adalimumab) holds a 98% share of the US adalimumab market by volume nine months after the first biosimilar version of the drug became available, according to a quarterly biosimilars report from the biosmilar manufacturer Samsung Bioepis Co., Ltd..

Key Takeaways

  • AbbVie’s Humira has demonstrated notable resiliency against biosimilar competition in the first year.

The market share figure highlights the strength of AbbVie’s branded drug to stand up against biosimilar competition in the US...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip